Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

(2012) A Ward et al.   ONCOGENE

Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells

(2012) Takehiro Ichikawa et al.   PLoS One

Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer

(2012) Xiao-Feng Le et al.   PLoS One

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

(2011) Joan T. Garrett et al.   CANCER BIOLOGY & THERAPY

MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor

(2011) Kar Lok Kong et al.   GUT

Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer

(2011) Chang Gong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Gene bi-targeting by viral and human miRNAs

(2010) Isana Veksler-Lublinsky et al.   BMC BIOINFORMATICS

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Characterization of a Candidate Tumor Suppressor Gene Uroplakin 1A in Esophageal Squamous Cell Carcinoma

(2010) K. L. Kong et al.   CANCER RESEARCH

FoxM1 Mediates Resistance to Herceptin and Paclitaxel

(2010) Janai R. Carr et al.   CANCER RESEARCH

MicroRNA-375 Is Downregulated in Gastric Carcinomas and Regulates Cell Survival by Targeting PDK1 and 14-3-3 

(2010) Y. Tsukamoto et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

(2010) D. B. Ulanet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer

(2009) Guohong Hu et al.   CANCER CELL

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Therapeutic options for metastatic breast cancer

(2009) Patrick G Morris et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas

(2009) Tali Avnit-Sagi et al.   PLoS One